Evaluation of serum diagnosis of pancreatic cancer by using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry

Gao,Hongjun; Zheng,Zhaoxu; Yue,Zhigang; Liu,Fang; Zhou,Lanping; Zhao,Xiaohang

doi:10.3892/ijmm.2012.1113

Evaluation of serum diagnosis of pancreatic cancer by using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry

Authors:
- Hongjun Gao
- Zhaoxu Zheng
- Zhigang Yue
- Fang Liu
- Lanping Zhou
- Xiaohang Zhao
View Affiliations

Affiliations: Clinical Laboratory of Coal General Hospital, Beijing, P.R. China, Department of Abdominal Surgery, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China, State Key Laboratory of Molecular Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China
Published online on: August 30, 2012 https://doi.org/10.3892/ijmm.2012.1113
Pages: 1061-1068

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Proteomic methods have been widely used in disease marker discovery research. The aim of this study was to discover potential biomarkers for pancreatic cancer (PCa) using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS). Crude serum samples from 132 patients with PCa and 67 healthy controls (HCs) were analyzed in duplicate using SELDI. Support vector machine (SVM) analysis of the spectra was used to generate a predictive algorithm based on proteins that were maximally differentially expressed between patients with PCa and the HCs in the training cohort. This algorithm was tested using leave-one-out cross-validation in the test cohort. From the 4 significant peaks in the training cohort, a classifier for separating patients with PCa from HCs was developed. The classifier was challenged with all samples achieving 96.67% sensitivity and 100% specificity in the training cohort and 93.1% sensitivity and 78.57% specificity in the test cohort. Additionally, the classifier correctly classified 12/12 stage Ia and 13/16 stage IIa PCa cases. The combination of the SELDI panel and CA19-9 was superior to CA19-9 alone in distinguishing individuals with PCa from the healthy subject group. These results suggest that high-throughput proteomic profiling has the capacity to provide new biomarkers for the early detection and diagnosis of PCa.

View Figures

View References

1.	D LiK XieR WolffJL AbbruzzesePancreatic cancerLancet36310491057200410.1016/S0140-6736(04)15841-8
2.	TP YeoRH HrubanSD LeachPancreatic cancerCurr Probl Cancer26176275200210.1067/mcn.2002.12957912399802
3.	RA AbramsLB GrochowA ChakravarthyIntensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levelsInt J Radiat Oncol Biol Phys4410391046199910.1016/S0360-3016(99)00107-8
4.	DK PleskowHJ BergerJ GyvesE AllenA McLeanDK PodolskyEvaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancerAnn Intern Med110704709198910.7326/0003-4819-110-9-7042930108
5.	M AkdoganN SasmazB KayhanI BiyikogluS DisibeyazB SahinExtraordinarily elevated CA19-9 in benign conditions: a case report and review of the literatureTumori87337339200111765186
6.	XG NiXF BaiYL MaoThe clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancerEur J Surg Oncol31164169200510.1016/j.ejso.2004.09.00715698733
7.	E Petricoin IIILA LiottaCounterpoint: The vision for a new diagnostic paradigmClin Chem4912761278200310.1373/49.8.127612881442
8.	CJ ScarlettRC SmithA SaxbyProteomic classification of pancreatic adenocarcinoma tissue using protein chip technologyGastroenterology13016701678200610.1053/j.gastro.2006.02.03616697731
9.	S BhattacharyyaER SiegelGM PetersenST ChariLJ SuvaRS HaunDiagnosis of pancreatic cancer using serum proteomic profilingNeoplasia6674686200410.1593/neo.0426215548376
10.	J KoopmannZ ZhangN WhiteSerum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometryClin Cancer Res10860868200410.1158/1078-0432.CCR-1167-3
11.	Y YuS ChenLS WangPrediction of pancreatic cancer by serum biomarkers using surface-enhanced laser desorption/ionization-based decision tree classificationOncology687986200510.1159/000084824
12.	K HondaY HayashidaT UmakiPossible detection of pancreatic cancer by plasma protein profilingCancer Res651061310622200510.1158/0008-5472.CAN-05-185116288055
13.	M EhmannK FelixD HartmannIdentification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profilingPancreas34205214200710.1097/01.mpa.0000250128.57026.b217312459
14.	J SongM PatelCN RosenzweigQuantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassayClin Chem5210451053200610.1373/clinchem.2005.065722
15.	M DongY NioK TamuraKi-ras point mutation and p53 expression in human pancreatic cancer: a comparative study among Chinese, Japanese, and Western patientsCancer Epidemiol Biomarkers Prev9279284200010750666
16.	P HeHZ HeJ DaiThe human plasma proteome: analysis of Chinese serum using shotgun strategyProteomics534423453200510.1002/pmic.20040130116047309
17.	JX WangJK YuL WangQL LiuJ ZhangS ZhengApplication of serum protein fingerprint in diagnosis of papillary thyroid carcinomaProteomics653445349200610.1002/pmic.20050083316941571
18.	KA BaggerlyJS MorrisKR CoombesReproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experimentsBioinformatics20777785200410.1093/bioinformatics/btg48414751995
19.	S BraunFD VoglB NaumeA pooled analysis of bone marrow micrometastasis in breast cancerN Engl J Med353793802200510.1056/NEJMoa05043416120859
20.	T SingO SanderN BeerenwinkelT LengauerROCR: visualizing classifier performance in RBioinformatics2139403941200510.1093/bioinformatics/bti62316096348
21.	P PavlidisI WapinskiWS NobleSupport vector machine classification on the webBioinformatics20586587200410.1093/bioinformatics/btg46114990457
22.	M WagnerDN NaikA PothenComputational protein biomarker prediction: a case study for prostate cancerBMC Bioinformatics526200410.1186/1471-2105-5-2615113409
23.	NT ZinkinF GrallK BhaskarSerum proteomics and biomarkers in hepatocellular carcinoma and chronic liver diseaseClin Cancer Res14470477200810.1158/1078-0432.CCR-07-058618223221
24.	C RostyL ChristaS KuzdzalIdentification of hepato-carcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technologyCancer Res62186818752002
25.	C MelleG ErnstN EscherProtein profiling of microdissected pancreas carcinoma and identification of HSP27 as a potential serum markerClin Chem53629635200710.1373/clinchem.2006.07919417303689
26.	EF PetricoinAM ArdekaniBA HittUse of proteomic patterns in serum to identify ovarian cancerLancet359572577200210.1016/S0140-6736(02)07746-211867112
27.	BL AdamY QuJW DavisSerum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy menCancer Res62360936142002
28.	AJ RaiPM StemmerZ ZhangAnalysis of Human Proteome Organization Plasma Proteome Project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization-time of flight (SELDI-TOF) mass spectrometry: multi-institution correlation of spectra and identification of biomarkersProteomics5346734742005
29.	OJ SemmesZ FengBL AdamEvaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibilityClin Chem51102112200510.1373/clinchem.2004.038950
30.	M AivadoD SpentzosG AlterovitzOptimization and evaluation of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) with reversed-phase protein arrays for protein profilingClin Chem Lab Med43133140200510.1515/CCLM.2005.022
31.	DG WardY ChengG N’KontchouChanges in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosisBr J Cancer94287292200610.1038/sj.bjc.660292316404431
32.	J AlbrethsenR BogeboJ OlsenH RaskovS GammeltoftPreanalytical and analytical variation of surface-enhanced laser desorption-ionization time-of-flight mass spectrometry of human serumClin Chem Lab Med4412431252200610.1515/CCLM.2006.22817032137
33.	DG WardY ChengG N’KontchouPreclinical and post-treatment changes in the HCC-associated serum proteomeBr J Cancer9513791383200610.1038/sj.bjc.660342917060939
34.	J RobozMass spectrometry in diagnostic oncoproteomicsCancer Invest23465478200510.1081/CNV-6718216193645
35.	MP EbertJ MeuerJC WiemerIdentification of gastric cancer patients by serum protein profilingJ Proteome Res312611266200410.1021/pr049865s15595736
36.	GL HortinThe MALDI-TOF mass spectrometric view of the plasma proteome and peptidomeClin Chem5212231237200610.1373/clinchem.2006.06925216644871
37.	EF PetricoinLA LiottaSELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancerCurr Opin Biotechnol152430200410.1016/j.copbio.2004.01.00515102462
38.	EE SchweglerL CazaresLF SteelSELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinomaHepatology41634642200510.1002/hep.2057715726646